<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS207096</article-id><article-id pub-id-type="doi">10.1101/2025.07.02.662774</article-id><article-id pub-id-type="archive">PPR1046959</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>RNA liquid biopsy via nanopore sequencing for novel biomarker discovery and cancer early detection</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Peddu</surname><given-names>Vikas</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hill</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Velandi Maroli</surname><given-names>Sree Lakshmi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mattingly</surname><given-names>Connor</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gardner</surname><given-names>Joshua M.V.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Miga</surname><given-names>Karen H.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fitzgerald</surname><given-names>Rebecca C.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Daniel H.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Biomolecular Engineering, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03s65by71</institution-id><institution>University of California Santa Cruz</institution></institution-wrap>, <city>Santa Cruz</city>, <state>CA</state>, <country country="US">USA</country></aff><aff id="A2"><label>2</label>Early Cancer Institute, Department of Oncology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap>, <city>Cambridge</city>, <country country="GB">UK</country></aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author: <email>daniel.kim@ucsc.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>11</day><month>07</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>05</day><month>07</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Liquid biopsies detect disease noninvasively by profiling cell-free nucleic acids that are secreted into the circulation. However, existing methods exhibit low sensitivity for detecting early stages of diseases such as cancer. Here we show that long-read nanopore sequencing of full-length cell-free RNA in plasma from healthy individuals, precancerous Barrett’s esophagus patients with high-grade dysplasia, or patients with esophageal adenocarcinoma reveals a diverse cell-free RNA transcriptome that can be leveraged for detecting and treating disease. We discovered 270,679 novel, intergenic cell-free RNAs, which we used to build a custom transcriptome reference for quantification, feature selection, and machine learning to accurately classify both precancer and cancer. Moreover, we found potential therapeutic targets, including metabolic, signaling, and immune checkpoint pathways, that are highly upregulated in both precancer and cancer patients. Our findings highlight the utility of our RNA liquid biopsy platform technology for discovering and targeting early stages of disease with molecular precision.</p></abstract></article-meta></front><body><p id="P2">Esophageal cancer is the sixth leading cause of cancer-related death around the world, with a 5-year survival rate of approximately 20%<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. An estimated 544,100 people died from esophageal cancer in 2020, and current projections estimate that 880,000 people will die from esophageal cancer in 2040<sup><xref ref-type="bibr" rid="R2">2</xref></sup>, highlighting the need for better methods to detect and treat esophageal cancer at the earliest signs of disease. Gastroesophageal reflux disease can lead to precancerous Barrett’s esophagus and dysplasia, which progressively increases the risk of developing esophageal adenocarcinoma<sup><xref ref-type="bibr" rid="R3">3</xref></sup>. However, currently available liquid biopsy methods based on cell-free DNA sequencing detect early-stage cancers with low sensitivity and do not provide comprehensive insights into potential therapeutic targets<sup><xref ref-type="bibr" rid="R4">4</xref></sup>.</p><p id="P3">Liquid biopsy technologies based on cell-free RNA (cfRNA) sequencing show promise for the detection of certain cancers and precancerous conditions<sup><xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R12">12</xref></sup>. cfRNA is actively secreted by cells into the circulation and protected from degradation by being encapsulated in extracellular vesicles (EVs), which are nanometer-sized lipid bilayer particles that reflect the state of their cell of origin<sup><xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref></sup>. cfRNAs are comprised of various classes of short and long RNAs, including protein-coding RNAs, long noncoding RNAs (lncRNAs)<sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>, and repeat element-derived RNAs<sup><xref ref-type="bibr" rid="R18">18</xref>–<xref ref-type="bibr" rid="R21">21</xref></sup>. Although repeat-aware RNA liquid biopsy technologies such as COMPLETE-seq<sup><xref ref-type="bibr" rid="R5">5</xref></sup> enable the accurate classification of certain cancer types, including lung, liver, colorectal, and stomach cancers, other cancers such as esophageal cancer exhibit lower sensitivity, highlighting the need for novel approaches that enable cancer early detection with high sensitivity and specificity.</p><p id="P4">Current RNA liquid biopsy approaches are also constrained by the use of targeted approaches and/or short-read sequencing technologies, which are unable to sequence full-length cell-free RNAs that are longer than a few hundred nucleotides in length. Single-molecule, long-read nanopore sequencing enables full-length cell-free RNA sequencing, and here we show that nanopore sequencing can be leveraged to comprehensively characterize the vast, unannotated cell-free RNA transcriptome across healthy, precancerous, and cancerous disease states. By discovering and incorporating over 270,000 novel, unannotated cell-free RNAs into a custom transcriptome reference for quantification, feature selection, and machine learning, we demonstrate that cell-free RNAs enable highly accurate early detection of both precancerous high-grade dysplasia and esophageal adenocarcinoma, while providing systemic molecular insights into potential therapeutic targets and the progression from precancer to cancer.</p><sec id="S1" sec-type="results"><title>Results</title><sec id="S2"><title>LOCATE-seq RNA liquid biopsy platform for disease discovery</title><p id="P5">We developed a new RNA liquid biopsy platform technology called LOCATE-seq that harnesses <underline>lo</underline>ng-read sequencing of <underline>c</underline>ell-free RNA to <underline>a</underline>nnotate and quantify known and novel transcripts to <underline>e</underline>nable disease detection / monitoring, treatment selection, and drug discovery (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). We isolated cell-free RNA from the plasma of 16 healthy individuals, 12 patients diagnosed with precancerous Barrett’s esophagus with high-grade dysplasia, and 19 patients diagnosed with esophageal adenocarcinoma (n=13 stage I, n=5 stage II, n=1 stage III) (<xref ref-type="table" rid="T1">Table 1</xref>). We generated full-length cDNA libraries for long-read nanopore sequencing on the PromethION 48 sequencer. For novel transcript discovery<sup><xref ref-type="bibr" rid="R22">22</xref></sup>, we compiled all 47 nanopore sequencing libraries (40.7 million total reads), which revealed 276,346 previously unannotated transcripts that were not found in the GENCODE 39 annotation of the human transcriptome. Of these novel cfRNA transcripts, 270,679 occurred in intergenic regions.</p><p id="P6">We next generated a custom transcriptome reference by combining our 276,346 novel cfRNA transcripts with all of the known transcripts in GENCODE 39, substantially expanding the known human cfRNA transcriptome. To more deeply profile our healthy and patient plasma samples, we then performed high-depth, short-read sequencing of our cfRNA libraries on the NovaSeq X sequencer (1.26 billion total reads) and mapped them to either the GENCODE transcriptome reference or our custom cfRNA transcriptome reference (GENCODE + Novel cfRNA) for quantification of both well-annotated GENCODE biotypes and the novel cfRNAs we discovered using long-read nanopore sequencing of full-length cfRNA. The median numbers of detected protein-coding genes were comparable whether we used the GENCODE transcriptome reference (healthy: 13,772, dysplasia: 12,342, cancer: 13,388) or our custom GENCODE + novel cfRNA transcriptome reference (healthy: 13,779, dysplasia: 11,892, cancer: 13,046) for cfRNA quantification (<xref ref-type="fig" rid="F1">Fig. 1b</xref>). Median lncRNA genes detected were also comparable between GENCODE (healthy: 6,964, dysplasia: 5,540, cancer: 6,256) and GENCODE + novel cfRNA (healthy: 6,673, dysplasia: 5,074, cancer: 5,797) quantification (<xref ref-type="fig" rid="F1">Fig. 1c</xref>). For novel cfRNAs, the number of detected genes was highest in healthy individuals (median: 157,821) when compared to dysplasia (median: 115,184) and cancer (median: 143,431) patients (<xref ref-type="fig" rid="F1">Fig. 1d</xref>). Novel cfRNAs were distributed throughout the genome (<xref ref-type="fig" rid="F1">Fig. 1e</xref>), with the majority of novel cfRNAs less than 1,000 nucleotides (nt) in length (<xref ref-type="fig" rid="F1">Fig. 1f</xref>).</p></sec><sec id="S3"><title>Mitochondrial RNA enrichment in dysplasia and cancer</title><p id="P7">Quantification of cfRNA using the GENCODE transcriptome reference and subsequent differential expression (DE) analysis revealed significant enrichment of mitochondrial and protein-coding RNA in precancerous high-grade dysplasia (<xref ref-type="fig" rid="F2">Fig. 2a</xref>), esophageal cancer (<xref ref-type="fig" rid="F2">Fig. 2b</xref>), and both dysplasia and cancer cfRNA (<xref ref-type="fig" rid="F2">Fig. 2c</xref>) when compared to healthy individuals. The mitochondrial cfRNA signal was the most significantly enriched molecular signature across all three DE analyses, indicating that mitochondrial cfRNAs that are strongly secreted at the precancerous state continue to persist in esophageal cancer patients. Protein-coding RNAs were the most commonly enriched across each of the DE analyses (<xref ref-type="fig" rid="F2">Fig. 2d</xref>), while lncRNAs were the most commonly depleted across each of the comparisons (<xref ref-type="fig" rid="F2">Fig. 2e</xref>). Significantly more mitochondrial genes were represented in the cfRNA of patients with precancerous dysplasia or cancer (<xref ref-type="fig" rid="F2">Fig. 2f</xref>), suggesting that mitochondrial RNAs may serve as highly abundant biomarkers for both precancer and cancer early detection. Notably, a subset of dysplasia and cancer patients exhibited substantially higher levels of mitochondrial RNA in their cfRNA transcriptomes, while other patients showed more moderate levels of mitochondrial RNA enrichment (<xref ref-type="fig" rid="F2">Fig. 2g</xref>).</p></sec><sec id="S4"><title>Differential abundance of novel cfRNA in dysplasia and cancer</title><p id="P8">We next used our custom transcriptome reference containing all of our novel cfRNA transcripts (GENCODE + novel cfRNA) for quantification and DE analysis in precancerous high-grade dysplasia when compared to healthy (<xref ref-type="fig" rid="F3">Fig. 3a</xref>), esophageal cancer when compared to healthy (<xref ref-type="fig" rid="F3">Fig. 3b</xref>), and when comparing healthy to both dysplasia and cancer cfRNA (<xref ref-type="fig" rid="F3">Fig. 3c</xref>). Protein-coding RNAs were again the most commonly enriched in disease across each of the comparisons (<xref ref-type="fig" rid="F3">Fig. 3d</xref>), while novel cfRNAs were significantly depleted in dysplasia or cancer cfRNA (<xref ref-type="fig" rid="F3">Fig. 3e</xref>). We also found a cluster of 20 novel cfRNAs that exhibited higher overall expression across both dysplasia and cancer patients (<xref ref-type="fig" rid="F3">Fig. 3f</xref>).</p></sec><sec id="S5"><title>Novel cfRNA features enable accurate disease classification</title><p id="P9">When we examined novel cfRNAs that were unique to each individual, we observed a significant increase in unique novel cfRNAs in esophageal cancer patients (<xref ref-type="fig" rid="F4">Fig. 4a</xref>), with a few patients expressing over 1,000 unique novel cfRNAs (<xref ref-type="fig" rid="F4">Fig. 4b</xref>). Using a feature set that contained both well-annotated GENCODE transcripts and our novel cfRNA transcripts, we trained machine learning models (logistic regression) with L1 regularization using the significantly DE cfRNAs as input features (p-adjusted &lt; 0.05). Our models segregated both high-grade dysplasia (<xref ref-type="fig" rid="F4">Fig. 4c</xref>) and esophageal cancer (<xref ref-type="fig" rid="F4">Fig. 4d</xref>) from healthy samples with perfect sensitivity (100%) and specificity (100%) using a limited number of features, highlighting the utility of our approach for both precancer and cancer early detection using noninvasive RNA liquid biopsy technology.</p></sec><sec id="S6"><title>Dysregulated pathways as potential therapeutic targets in dysplasia and cancer</title><p id="P10">We next characterized common gene sets and pathways that were significantly dysregulated in both high-grade dysplasia and early-stage esophageal cancer patients to identify potential therapeutic targets. We performed gene seat enrichment analysis (GSEA) and found that “MYC targets” and the mitochondrial process of “oxidative phosphorylation” were the top 2 enriched gene sets across both dysplasia and early-stage cancer (<xref ref-type="fig" rid="F5">Fig. 5a</xref>). “PI3K AKT MTOR signaling” and “MTORC1 signaling” were also among the top 10 enriched gene sets in both dysplasia and cancer (<xref ref-type="fig" rid="F5">Fig. 5a</xref>). The plasma cfRNA levels of biomarkers such as human epidermal growth factor-2 (HER2) remained relatively constant between healthy individuals and patients with dysplasia or cancer (<xref ref-type="fig" rid="F5">Fig. 5b</xref>), but the cfRNA levels of immunotherapy biomarkers such as the immune checkpoint genes CTLA-4 (<xref ref-type="fig" rid="F5">Fig. 5c</xref>) and LAG-3 (<xref ref-type="fig" rid="F5">Fig. 5d</xref>) increased in the plasma of Barrett’s esophagus patients with high-grade dysplasia. Plasma cfRNA levels for immune checkpoint genes PD-L1 (<xref ref-type="fig" rid="F5">Fig. 5e</xref>) and TIGIT (<xref ref-type="fig" rid="F5">Fig. 5f</xref>) and the p53 regulator MDM2 (<xref ref-type="fig" rid="F5">Fig. 5g</xref>) were relatively consistent across all of the sample cohorts, although a few cancer patients exhibited much higher levels of these biomarkers.</p></sec></sec><sec id="S7" sec-type="discussion"><title>Discussion</title><p id="P11">Here we show that the comprehensive profiling of cfRNA using full-length nanopore sequencing enables the discovery of 276,346 unannotated, novel cfRNA transcripts, many of which are differentially expressed in disease and can be leveraged as biomarkers for precancer and cancer early detection with high sensitivity and specificity using machine learning. Our findings reveal that our understanding of the true complexity of cfRNA transcriptomes in the context of health and disease is still nascent, and by using single-molecule, long-read nanopore sequencing of full-length cfRNA, we reveal the dynamic diversity of cfRNA transcriptomes in healthy individuals and patients with precancerous high-grade dysplasia or esophageal adenocarcinoma. Our LOCATE-seq RNA liquid biopsy platform technology allows us to profile and harness this rich diversity of cfRNA for novel biomarker discovery and highly accurate disease classification.</p><p id="P12">Our study also reveals that mitochondrial RNA are highly enriched in the cfRNA in both precancerous dysplasia and early-stage cancer patient plasma, highlighting their utility as biomarkers of disease and underscoring their role in providing potential insights into metabolic changes and disease biology. A recent study using the PC3 prostate cancer cell line also showed that mitochondrial RNA are enriched in large oncosomes, suggesting that mitochondrial RNA may serve as circulating biomarkers for various types of cancers<sup><xref ref-type="bibr" rid="R23">23</xref></sup>. Increased levels of mitochondria-derived cfRNA and the enrichment of gene sets such as oxidative phosphorylation in dysplasia and cancer also suggest potential therapeutic strategies for disease treatment using drugs that target this metabolic pathway. Our findings also uncover additional pathways for potential therapeutic intervention, including enrichment of the PI3K AKT MTOR signaling pathway in both dysplasia and cancer, and increased levels of immune checkpoint pathway genes such as CTLA-4 and LAG-3 in precancerous dysplasia, suggesting the potential utility of immunotherapy for esophageal cancer prevention.</p><p id="P13">Taken together, our study provides proof-of-concept that long-read nanopore sequencing of cfRNA reveals a rich diversity of previously unknown cfRNA transcripts that can serve as new biomarkers and novel features for precancer and cancer early detection using machine learning / artificial intelligence. Further validation using plasma samples from independent patient cohorts will be important for validating and testing the performance of our models. Our study also demonstrates the advantages of comprehensively profiling the cfRNA transcriptome for drug target discovery and for informing potential therapeutic strategies for cancer treatment and prevention.</p></sec><sec id="S8" sec-type="methods"><title>Methods</title><sec id="S9"><title>Cell-free RNA isolation</title><p id="P14">Blood plasma from patients were collected from Cambridge University Hospital. Healthy donors were identified as those without disease by BioIVT sample metadata. Plasma samples were initially run through a 0.8μm filter to remove cellular debris. Cell-free RNA was isolated from the filtered plasma using the Norgen Biotek Plasma/Serum Circulating and Exosomal RNA Purification Kit (slurry format). RNA was eluted into 50 μl and stored at –80C prior to cDNA synthesis.</p></sec><sec id="S10"><title>cDNA synthesis</title><p id="P15">10 ng of input RNA was used for the Takara SMART-Seq HT plus kit. cDNA was prepared as specified by the manufacturer’s protocol and amplified for 24 cycles. Quantification of the resulting cDNA was done using both a Nanodrop spectrophotometer, as well as a Qubit Fluorometer. The size distribution of the cDNA was verified using an Agilent Bioanalyzer prior to sequencing library preparation.</p></sec><sec id="S11"><title>Long-read sequencing</title><p id="P16">Barcoded nanopore sequencing libraries were created using a custom low-input protocol for the Oxford Nanopore Technologies SQK-NBD-114.24 and LSK-114 kits. Briefly, cDNA was end-repaired and A-tailed as specified, but incubated for 30 minutes, followed by a 30-minute deactivation. Barcodes from the SQK-NBD-114.24 kit were incubated at 20 C for 4.5 hours.</p><p id="P17">Ligation was terminated by the addition of 2ul of EDTA to each reaction. Barcoded samples were pooled and subject to a 1.8x Ampure Bead cleanup, and then used as input for the LSK-114 protocol. Here, we modified all bead cleanups to use a 1.8x ratio and performed all bead washes at 37 C. Adapter ligation was performed for 20 minutes to promote ligation yield. Short fragment buffer was used to capture the full gamut of cDNA lengths. The final library was eluted into 25ul of elution buffer and loaded onto an R10.4 Promethion flow cell. POD5s were basecalled and demultiplexed using Dorado version 0.5.3 using the SUPv4.3.0 basecalling model. Reads that failed demultiplexing were re-demultiplexed using a custom python script that exact matches barcodes and later combined with their respective FASTQs.</p></sec><sec id="S12"><title>Short-read sequencing</title><p id="P18">Illumina libraries were prepared using full-length cDNA generated from the isolated plasma RNA of healthy, Barrett’s esophagus, and esophageal cancer samples using the Takara SMART-Seq HT plus kit and sequenced on an Illumina NovaSeq (2x150 bp reads).</p></sec><sec id="S13"><title>Novel transcript discovery</title><p id="P19">Isoquant version 3.3.1 with the Human reference genome build HG38 and the GENCODE version 39 comprehensive transcript annotation set was used to identify novel transcripts against all FASTQs in one batch with the following parameters:</p><p id="P20">-d nanopore, –stranded none, --report_novel_unspliced true, –matching_strategy loose, -- gene_quantification all, --transcript_quantification all.</p><p id="P21">Novel transcripts were merged with the GENCODE annotations. Assembly quality was assessed using SQANTI version 3 with default parameters.</p></sec><sec id="S14"><title>RNA-seq quality and quantification</title><p id="P22">RNA-seq short reads (FASTQ) were trimmed using FastP (v0.23.4), assessed for quality using FastQC (v0.12.1), and quantified using Salmon (v1.10.1). Quantification was run with the following parameters:</p><p id="P23">--gcBias, --seqBias, --validateMappings, --recoverOrphans, --rangeFactorizationBins 4 To reduce sequences biases, enable selective alignments, rescue reads with an unmapped pair, and improve quantification accuracy. The salmon mappings were performed against a concatenation of: <list list-type="order" id="L1"><list-item><p id="P24">the HG38 human genome reference annotation (v39) from the GENCODE consortium, and the RepeatMasker track from the University of California Santa Cruz genome browser</p></list-item><list-item><p id="P25">The above, and an annotation of novel genes identified via IsoQuant (3.3.1)</p></list-item></list></p><p id="P26">This assembled a transcriptome annotated with the corresponding ENSEMBL transcript IDs and novel gene IDs from IsoQuant. Transcript counts were aggregated to the gene level for GENCODE genes.</p></sec><sec id="S15"><title>Short-read analysis</title><p id="P27">Short-read transcripts were imported into R (v4.3.3) using tximport (v1.22.0). Biotypes were assigned to genes using their respective GENCODE biotypes. IsoQuant annotated novel genes were assigned the ‘Novel’ biotype. Count normalization and differential expression analyses were performed using DESeq2 (v1.42.0). Significant differential expression was limited to genes with a Benjamini-Hochberg adjusted p-value &lt; 0.05, and an absolute value log2 fold-change &gt; 1.</p></sec><sec id="S16"><title>Modeling</title><p id="P28">Logistic regression models were train in R using the glmnet package (v4.1), with the identified differentially expressed genes as input features. Models were trained with respect to the sample age and sex (~condition+age+sex). One sample was missing the age information in the metadata, and the average age of samples with the same histology and sex was used. Optimal lambda values for the logistic regression model were identified using 5-fold cross validation, and the value 1 standard error away from the minimum cross-validated value of lambda was selected for final model training. The final model was trained utilizing the entire dataset, and further feature reduction was performed using LASSO regression.</p></sec></sec></body><back><ack id="S17"><title>Acknowledgements</title><p>We thank Hannah Coles, Adam Freeman, and the OCCAMS consortium for providing plasma samples and anonymized data, and infrastructure was supported by Cancer Research UK (CRUK) on behalf of the OCCAMS consortium. This work was supported by Cancer Research UK [A15874, A22720, A22131] and the Medical Research Council [MR/W014122/1] to R.C.F. with additional support by the UK National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (NIHR203312), and the American Cancer Society (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.53354/pc.gr.158353">https://doi.org/10.53354/pc.gr.158353</ext-link>) and philanthropic support to D.H.K. V.P. was supported by the Tobacco-Related Disease Research Program (T32DT4904), A.H. was supported by the UCSC Committee of Research Large Grant Program (09507-444096), S.V.M. was supported by the California Institute for Regenerative Medicine (EDUC4-12759), and D.H.K. was supported by a Research Scholar Grant (RSG-22-099-01-CDP) from the American Cancer Society.</p></ack><sec id="S18" sec-type="data-availability"><title>Data availability</title><p id="P29">Nanopore long read sequencing data have been deposited at the NCBI Gene Expression Omnibus repository under accession number GSE271389 and Illumina short read sequencing data under accession number GSE271390.</p></sec><fn-group><fn fn-type="con" id="FN1"><p id="P30"><bold>Author Contributions</bold></p><p id="P31">D.H.K. conceived and designed the study, V.P. and A.H. performed computational analyses and generated figures, S.V.M. and C.M. performed experiments, J.G., K.M., and R.F. provided materials, D.H.K. supervised research, and D.H.K., V.P., and A.H. wrote the paper with input from the authors.</p></fn><fn fn-type="conflict" id="FN2"><p id="P32"><bold>Competing Interests</bold></p><p id="P33">D.H.K., V.P., and A.H. are inventors on patent applications regarding RNA liquid biopsy platform technologies submitted by the Regents of the University of California. R.C.F. is named on patents related to Cytosponge and related assays which have been licensed by the Medical Research Council to Covidien GI Solutions (now Medtronic) and is a co-founder and share holder (&lt;2%) of CYTED Ltd. D.H.K. is a founder, shareholder, and board member of LincRNA Bio and has received research support/reagents from Oxford Nanopore Technologies, Tempus AI, nRichDX, and Takara Bio, travel support from Oxford Nanopore Technologies and Tempus AI, and honoraria from Veracyte and Genentech/Roche.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Improving outcomes in patients with oesophageal cancer</article-title><source>Nat Rev Clin Oncol</source><year>2023</year><volume>20</volume><fpage>390</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">37085570</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>E</given-names></name><etal/></person-group><article-title>The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020</article-title><source>Gastroenterology</source><year>2022</year><volume>163</volume><fpage>649</fpage><lpage>658</lpage><elocation-id>e642</elocation-id><pub-id pub-id-type="pmid">35671803</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killcoyne</surname><given-names>S</given-names></name><name><surname>Fitzgerald</surname><given-names>RC</given-names></name></person-group><article-title>Evolution and progression of Barrett’s oesophagus to oesophageal cancer</article-title><source>Nat Rev Cancer</source><year>2021</year><volume>21</volume><fpage>731</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">34545238</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA</article-title><source>Ann Oncol</source><year>2020</year><volume>31</volume><fpage>745</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.02.011</pub-id><pub-id pub-id-type="pmcid">PMC8274402</pub-id><pub-id pub-id-type="pmid">33506766</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reggiardo</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Profiling of repetitive RNA sequences in the blood plasma of patients with cancer</article-title><source>Nat Biomed Eng</source><year>2023</year><volume>7</volume><fpage>1627</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1038/s41551-023-01081-7</pub-id><pub-id pub-id-type="pmcid">PMC10727983</pub-id><pub-id pub-id-type="pmid">37652985</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roskams-Hieter</surname><given-names>B</given-names></name><etal/></person-group><article-title>Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies</article-title><source>NPJ Precis Oncol</source><year>2022</year><volume>6</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1038/s41698-022-00270-y</pub-id><pub-id pub-id-type="pmcid">PMC9038724</pub-id><pub-id pub-id-type="pmid">35468987</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anfossi</surname><given-names>S</given-names></name><name><surname>Babayan</surname><given-names>A</given-names></name><name><surname>Pantel</surname><given-names>K</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name></person-group><article-title>Clinical utility of circulating non-coding RNAs - an update</article-title><source>Nat Rev Clin Oncol</source><year>2018</year><volume>15</volume><fpage>541</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">29784926</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Chiu</surname><given-names>RW</given-names></name></person-group><article-title>The biology and diagnostic applications of plasma RNA</article-title><source>Ann N Y Acad Sci</source><year>2004</year><volume>1022</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">15251952</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulstaert</surname><given-names>E</given-names></name><etal/></person-group><article-title>Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas</article-title><source>Cell Rep</source><year>2020</year><volume>33</volume><elocation-id>108552</elocation-id><pub-id pub-id-type="pmid">33378673</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>MH</given-names></name><etal/></person-group><article-title>A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><elocation-id>2357</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22444-1</pub-id><pub-id pub-id-type="pmcid">PMC8060291</pub-id><pub-id pub-id-type="pmid">33883548</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loy</surname><given-names>C</given-names></name><name><surname>Ahmann</surname><given-names>L</given-names></name><name><surname>De Vlaminck</surname><given-names>I</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name></person-group><article-title>Liquid Biopsy Based on Cell-Free DNA and RNA</article-title><source>Annu Rev Biomed Eng</source><year>2024</year><volume>26</volume><fpage>169</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">38346275</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nesselbush</surname><given-names>MC</given-names></name><etal/></person-group><article-title>An ultrasensitive method for detection of cell-free RNA</article-title><source>Nature</source><year>2025</year><volume>641</volume><fpage>759</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">40240612</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches</article-title><source>Journal of Extracellular Vesicles</source><year>2024</year><volume>13</volume><elocation-id>e12404</elocation-id><pub-id pub-id-type="doi">10.1002/jev2.12404</pub-id><pub-id pub-id-type="pmcid">PMC10850029</pub-id><pub-id pub-id-type="pmid">38326288</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Liu</surname><given-names>BF</given-names></name><name><surname>Demirci</surname><given-names>U</given-names></name></person-group><article-title>Towards Microfluidic-Based Exosome Isolation and Detection for Tumor Therapy</article-title><source>Nano Today</source><year>2021</year><volume>37</volume><pub-id pub-id-type="doi">10.1016/j.nantod.2020.101066</pub-id><pub-id pub-id-type="pmcid">PMC7990116</pub-id><pub-id pub-id-type="pmid">33777166</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixson</surname><given-names>AC</given-names></name><name><surname>Dawson</surname><given-names>TR</given-names></name><name><surname>Di Vizio</surname><given-names>D</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group><article-title>Context-specific regulation of extracellular vesicle biogenesis and cargo selection</article-title><source>Nat Rev Mol Cell Biol</source><year>2023</year><volume>24</volume><fpage>454</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/s41580-023-00576-0</pub-id><pub-id pub-id-type="pmcid">PMC10330318</pub-id><pub-id pub-id-type="pmid">36765164</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reggiardo</surname><given-names>RE</given-names></name><name><surname>Maroli</surname><given-names>SV</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name></person-group><article-title>LncRNA Biomarkers of Inflammation and Cancer</article-title><source>Adv Exp Med Biol</source><year>2022</year><volume>1363</volume><fpage>121</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">35220568</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Long Noncoding RNAs: Molecular Modalities to Organismal Functions</article-title><source>Annu Rev Biochem</source><year>2020</year><volume>89</volume><fpage>283</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">32569523</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reggiardo</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes</article-title><source>Cell Reports</source><year>2022</year><volume>40</volume><elocation-id>111104</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111104</pub-id><pub-id pub-id-type="pmcid">PMC9374308</pub-id><pub-id pub-id-type="pmid">35858545</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reggiardo</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Epigenomic reprogramming of repetitive noncoding RNAs and IFN-stimulated genes by mutant KRAS</article-title><source>bioRxiv</source><year>2020</year><elocation-id>2020.2011.2004.367771</elocation-id><pub-id pub-id-type="doi">10.1101/2020.11.04.367771</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khojah</surname><given-names>R</given-names></name><etal/></person-group><article-title>Extracellular RNA signatures of mutant KRAS(G12C) lung adenocarcinoma cells</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.2002.2023.481574</elocation-id><pub-id pub-id-type="doi">10.1101/2022.02.23.481574</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Transposable element RNA dysregulation in mutant KRAS(G12C) 3D lung cancer spheroids</article-title><source>bioRxiv</source><year>2023</year><elocation-id>2023.2002.2027.530369</elocation-id><pub-id pub-id-type="doi">10.1101/2023.02.27.530369</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prjibelski</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Accurate isoform discovery with IsoQuant using long reads</article-title><source>Nat Biotechnol</source><year>2023</year><volume>41</volume><fpage>915</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01565-y</pub-id><pub-id pub-id-type="pmcid">PMC10344776</pub-id><pub-id pub-id-type="pmid">36593406</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Extracellular vesicle heterogeneity through the lens of multiomics</article-title><source>Cell Rep Med</source><year>2025</year><elocation-id>102161</elocation-id><pub-id pub-id-type="pmid">40482644</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><title>LOCATE-seq RNA liquid biopsy platform for disease discovery.</title><p>a. LOCATE-seq schematic. b. Number of protein-coding RNAs detected across patient samples and transcriptome references. c. Number of long noncoding RNAs detected across patient samples and transcriptome references. d. Number of novel cfRNAs detected across patient samples. e. Genomic distribution of novel cfRNAs. f. Size distributions of novel and GENCODE cfRNAs.</p></caption><graphic xlink:href="EMS207096-f001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><title>Mitochondrial RNA enrichment in dysplasia and cancer.</title><p>a. Differential expression (DE) analysis volcano plot of healthy vs. dysplasia cfRNA. b. DE analysis volcano plot of healthy vs. cancer cfRNA. c. DE analysis volcano plot of healthy vs dysplasia and cancer cfRNA. d. UpSet plot of common upregulated DE genes. e. UpSet plot of common downregulated DE genes. f. Box plot of number of detected mitochondrial genes. g. Hierarchical clustering of mitochondrial RNA expression.</p></caption><graphic xlink:href="EMS207096-f002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><title>Differential abundance of novel cfRNA in dysplasia and cancer.</title><p>a. Differential expression (DE) analysis volcano plot of healthy vs. dysplasia cfRNA. b. DE analysis volcano plot of healthy vs. cancer cfRNA. c. DE analysis volcano plot of healthy vs dysplasia and cancer cfRNA. d. UpSet plot of common upregulated DE genes. e. UpSet plot of common downregulated DE genes. f. Hierarchical clustering of novel cfRNA expression.</p></caption><graphic xlink:href="EMS207096-f003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><title>Novel cfRNA features enable accurate disease classification.</title><p>a. Box plot of number of detected unique novel cfRNAs. b. Bar plot of number of detected unique novel cfRNAs in each healthy individual or patient. c. Receiver operating characteristic curve for logistic regression model trained using known and novel cfRNA features for classification of high-grade dysplasia. d. Receiver operating characteristic curve for logistic regression model trained using known and novel cfRNA features for classification of early-stage esophageal cancer.</p></caption><graphic xlink:href="EMS207096-f004"/></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><title>Dysregulated pathways as potential therapeutic targets in dysplasia and cancer.</title><p>a. Gene set enrichment analysis for pathways enriched in dysplasia patient plasma (top 10 most significantly enriched pathways). b-g. Box plots of normalized counts for HER2, CTLA-4, LAG-3, PD-L1, TIGIT, and MDM2 cfRNA.</p></caption><graphic xlink:href="EMS207096-f005"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Patient plasma metadata.</title></caption><table frame="void" rules="none"><thead><tr><th valign="top" align="center"><underline>Sample ID</underline></th><th valign="top" align="center"><underline>Sex</underline></th><th valign="top" align="center"><underline>Age</underline></th><th valign="top" align="center"><underline>Histology</underline></th><th valign="top" align="center"><underline>Cancer Stage</underline></th></tr></thead><tbody><tr><td valign="top" align="center">A1</td><td valign="top" align="center">male</td><td valign="top" align="center">76.2</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A2</td><td valign="top" align="center">male</td><td valign="top" align="center">76.4</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A3</td><td valign="top" align="center">male</td><td valign="top" align="center">68.7</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A4</td><td valign="top" align="center">male</td><td valign="top" align="center">80.1</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A5</td><td valign="top" align="center">male</td><td valign="top" align="center">61.8</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">II</td></tr><tr><td valign="top" align="center">A6</td><td valign="top" align="center">male</td><td valign="top" align="center">56.5</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A7</td><td valign="top" align="center">female</td><td valign="top" align="center">82.1</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A8</td><td valign="top" align="center">female</td><td valign="top" align="center">52.4</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">II</td></tr><tr><td valign="top" align="center">A9</td><td valign="top" align="center">male</td><td valign="top" align="center">55.5</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A10</td><td valign="top" align="center">female</td><td valign="top" align="center">78.4</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A11</td><td valign="top" align="center">male</td><td valign="top" align="center">59.7</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">II</td></tr><tr><td valign="top" align="center">A12</td><td valign="top" align="center">female</td><td valign="top" align="center">59.7</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">II</td></tr><tr><td valign="top" align="center">A13</td><td valign="top" align="center">male</td><td valign="top" align="center">51</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A14</td><td valign="top" align="center">female</td><td valign="top" align="center">50.8</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A15</td><td valign="top" align="center">male</td><td valign="top" align="center">55.5</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A16</td><td valign="top" align="center">female</td><td valign="top" align="center">80.8</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">A17</td><td valign="top" align="center">male</td><td valign="top" align="center">75.3</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">II</td></tr><tr><td valign="top" align="center">A18</td><td valign="top" align="center">male</td><td valign="top" align="center">57.9</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">III</td></tr><tr><td valign="top" align="center">A19</td><td valign="top" align="center">male</td><td valign="top" align="center">83.2</td><td valign="top" align="center">adenocarcinoma</td><td valign="top" align="center">I</td></tr><tr><td valign="top" align="center">B1</td><td valign="top" align="center">male</td><td valign="top" align="center">85.3</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B2</td><td valign="top" align="center">male</td><td valign="top" align="center">61.4</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B3</td><td valign="top" align="center">male</td><td valign="top" align="center">70.3</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B4</td><td valign="top" align="center">male</td><td valign="top" align="center">64.5</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B5</td><td valign="top" align="center">male</td><td valign="top" align="center">49</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B6</td><td valign="top" align="center">male</td><td valign="top" align="center">68.4</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B7</td><td valign="top" align="center">male</td><td valign="top" align="center">82.8</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B8</td><td valign="top" align="center">male</td><td valign="top" align="center">67.9</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B9</td><td valign="top" align="center">male</td><td valign="top" align="center">61.9</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B10</td><td valign="top" align="center">male</td><td valign="top" align="center">88.4</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B11</td><td valign="top" align="center">male</td><td valign="top" align="center">59.2</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">B12</td><td valign="top" align="center">male</td><td valign="top" align="center">42.6</td><td valign="top" align="center">high grade dysplasia</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C1</td><td valign="top" align="center">male</td><td valign="top" align="center">72</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C2</td><td valign="top" align="center">male</td><td valign="top" align="center">70</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C3</td><td valign="top" align="center">male</td><td valign="top" align="center">74</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C4</td><td valign="top" align="center">male</td><td valign="top" align="center">81</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C5</td><td valign="top" align="center">male</td><td valign="top" align="center">84</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C6</td><td valign="top" align="center">female</td><td valign="top" align="center">89</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C7</td><td valign="top" align="center">male</td><td valign="top" align="center">86</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C8</td><td valign="top" align="center">male</td><td valign="top" align="center">72</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C9</td><td valign="top" align="center">male</td><td valign="top" align="center">60</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C10</td><td valign="top" align="center">male</td><td valign="top" align="center">52</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C11</td><td valign="top" align="center">female</td><td valign="top" align="center">57</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C13</td><td valign="top" align="center">female</td><td valign="top" align="center">72</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C14</td><td valign="top" align="center">female</td><td valign="top" align="center">80</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C15</td><td valign="top" align="center">male</td><td valign="top" align="center">82</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr><tr><td valign="top" align="center">C16</td><td valign="top" align="center">male</td><td valign="top" align="center">82</td><td valign="top" align="center">control</td><td valign="top" align="center"/></tr></tbody></table></table-wrap></floats-group></article>